Internal Requirements for Patentability (Oxford Law)

Internal Requirements for Patentability – Comprehensive Notes

Focus of the chapter: internal criteria for patentability (as opposed to external criteria like matter, novelty, inventive step). Examines how a patent is drafted, not just what is claimed.
Main internal criteria covered:
- Sufficiency of disclosure (enabling the invention for a person skilled in the art; scope of the monopoly should align with the disclosed contribution).
- Form and content of the claims: clarity, conciseness, support by the description, unity of invention.
- Prohibition on amendments that add new subject matter or extend the protection conferred by the patent.
Key terms used throughout: sufficiency of disclosure, classic sufficiency, Biogen sufficiency, enabling disclosure, fair basis, fair use of deposit, plausibility, unity of invention, product claims vs product-by-process, amendments, and depositaries.

Sufficiency of Disclosure

Core idea: The patent teaching must enable a person skilled in the art to perform the invention. This ties the extent of the monopoly to what the disclosure actually enables.
The patent bargain (bargain between patentee and public): a time-limited monopoly in exchange for full disclosure; after expiry, the public can work the invention using the disclosure. The scope of protection must correspond to the disclosure.
Lord Briggs (Regeneron) explains: if a patentee seeks a product monopoly, the teaching must enable production of the product; otherwise the public gets nothing substantive and earlier inventors are deterred.
The information disclosed must be useful; if a key element is missing or unduly burdensome to reproduce, sufficiency is fails.
Traditional British phrase: claims must be ‘fairly based’ on the disclosure; modern view links this to the patent bargain.
Primary test: does the specification enable a person skilled in the art to perform the invention? This is the enabling disclosure concept.
The scope of protection must align with the disclosure (i.e., not exceed what is taught).
Setup of the sufficiency inquiry: often divided into (i) classic insufficiency, (ii) insufficiency due to excessive claim breadth (Biogen insufficiency), or (iii) insufficiency due to uncertainty.
The notional skilled person uses knowledge of the prior art plus knowledge of the invention as disclosed (not just prior art alone).
Sufficiency is assessed as of the date of filing; onus initially on the applicant; at trial, the defendant bears the burden to show insufficiency with substantiated facts.
Verification standard: there must be serious doubts substantiated by verifiable facts to attack sufficiency; otherwise, patent stands.
The tests are framed in terms of enabling disclosure; the description must enable the invention to be made or used by a skilled person.
For determining sufficiency, three forms of insufficiency are recognized:
- Classic insufficiency: failure to enable the invention from common general knowledge.
- Biogen insufficiency: excessive breadth of claims relative to the disclosed technical contribution.
- Uncertainty: issues arising from unclear or vague claims that prevent a skilled person from knowing whether they have worked the invention.
Notion of enabling disclosure relies on the skilled person having both prior art knowledge and knowledge of the invention as disclosed; not just the prior art.
Sufficiency inquiry is linked to the problem the invention solves and to the nature of the invention (e.g., chemical, biological, or mechanical).
The sufficiency inquiry is connected to the requirement that the disclosure enable the invention to be manufactured or performed; this is sometimes described as the need for an enabling disclosure that enables the whole scope of the claimed invention.

General Principles (2.1)

The sufficiency test is judged as of filing date; the defendant bears the burden to show insufficiency with verifiable facts.
The ‘notional skilled person’ bears knowledge of prior art and the disclosed invention; they are assumed to be able to carry out routine tests and correct obvious errors in the specification.
The sufficiency inquiry often distinguishes between different problem types (classical, excessive breadth/ Biogen, uncertainty) but all tie back to enabling the invention.
The concept of enabling disclosure: if the skilled person cannot perform the invention from the disclosure, sufficiency fails.

Classical Insufficiency (2.2)

Classical insufficiency arises when the disclosure is not complete enough for a skilled person to perform the invention from common general knowledge.
Patentees are not required to show why the invention works; they must disclose enough to enable repetition of the invention.
The description need not spell out every detail; routine lab tests, correction of obvious errors, and use of common general knowledge are allowed.
The skilled person can use ordinary general knowledge to perform routine tests and to fill in obvious gaps; they need not be told what is self-evident.
For manufactured objects, the claims must enable a workable prototype; they do not need to be of saleable quality themselves.
Two important limitations on enabling activity by the skilled person:
- If the skilled person must use inventive skill to practice the invention, sufficiency fails.
- The invention must be reproducible without undue burden.
The timescale of experimentation must not be so burdensome as to make enablement impractical; a too-large project (even routine) can fail sufficiency.

Biological Inventions (2.2.1)

When biological material is involved (e.g., living microorganisms, plant/animal inventions), the description may not fully enable reproduction.
EPC and Patents Act address this by permitting deposit of biological material in a recognized institution (depositary) to satisfy sufficiency where description cannot fully enable replication.
Deposit requirements: if relying on deposit, the patent must reference the deposit; failure to reference may prevent reliance on the deposit.
Deposits form part of the prior art only after publication of the application.
The need for deposition depends on the nature of the invention; traditional for plant breeding, but not always necessary for molecular biology outcomes.
The Wisconsin Alumni Research Foundation/Stem Cell decision (T 1374/04) addressed whether a deposit is necessary to enable the skilled person to carry out stem cell cultures; the technical board accepted enablement under EPC Article 83 in that case, even with deposit not explicitly referenced in all aspects.
The extent of reliance on deposit depends on the invention’s nature and the availability of describing information; deposits are an option, not a requirement.

Insufficiency due to Excessive Breadth: ‘Biogen Insufficiency’ (2.3)

This form arises when the claims are broader than the disclosure and/or the inventor’s technical contribution would enable only part of the claimed scope.
Core idea: the breadth of the patent monopoly must be justified by the technical contribution to the art; otherwise, sufficiency may fail.
Process vs. product: a product claim should be enabled by disclosing at least one way of making the product; the scope should correspond to the disclosed technical contribution.
Key steps in the analysis (per EPO and UK judgments):
1) Determine the extent of the patent monopoly as defined by the claims.
2) Identify the patent’s disclosure and the technical contribution to the art.
3) Check whether the technical contribution is clearly and completely disclosed, i.e., whether the breadth of the monopoly matches the contribution.
The Generics (UK) v Lundbeck line illustrates the shift from focusing on the inventive step to focusing on the product itself as the technical contribution when a product claim is involved.
Generics (UK) v Lundbeck (various judgments: 2007 EWHC 1040; 2008 EWCA Civ 311; 2009 UKHL 12) clarified that for product claims the patent suffices if the patentee discloses one way to make the product; the “product is the invention” with ordinary enablement if the specification and common general knowledge enable the skilled person to make the product without undue burden.
The Biogen standard: a class of compounds or a broad product claim may be enabled if the patent discloses a unifying principle that applies generally to the whole class or range; otherwise, insufficiency may be found if it enables only some embodiments.
Generics v Lundbeck clarified that a patentee does not need to disclose all possible ways to make the product; a single enabling embodiment can suffice for enablement of a product claim.
The impact: a decision that the technical contribution is a product itself (not the process to make it) has consequences for the type of information required to satisfy sufficiency.

Extent of the Claim; Technical Contribution (2.3.1 – 2.3.2)

2.3.1 What is the extent of the claim?
- The extent of the monopoly is defined by the claims and should be determined in the same way as the scope of protection (as in Chapter 22).
2.3.2 What is the ‘technical contribution’?
- The technical contribution is what the invention contributes to the art; it is distinct from the inventor’s inventive concept.
- The Generics v Lundbeck discussion contrasts: (i) the elements of the invention that contributed to inventive step (method of making) vs (ii) the product (the enantiomer) itself as the invention.
- Lords Walker and Neuberger emphasize that the “technical contribution” is different from the “inventive concept”; one is about the core invention, the other about contributions to the art.
The practical implication: when assessing sufficiency for a product claim, the focus should be on the product itself as the invention; enablement requires only one way to make the product so long as the product is sufficiently disclosed.

Has there been a sufficient disclosure? (2.3.3)

After determining the scope and the technical contribution, the court asks whether the invention as claimed is disclosed clearly and completely enough to be performed by a skilled person.
The sufficiency standard requires enabling disclosure so that a skilled person can perform the invention without undue burden.
For product claims, sufficiency looks at whether the patent teaches the product and the enabling method to make it; for class claims, the court considers whether the class is sufficiently enabled across its scope.
If there is a risk that not all embodiments are enabled, this may threaten sufficiency; however, if a broad principle enabling general application is disclosed, enablement may be satisfied for all members of the class if the principle is properly described and demonstrated.

Product claims (2.3.4)

Product claims cover the article or substance per se and may extend to control how the product is made or used.
The issue with large product classes: whether the disclosure enables substantially all types within the claimed range.
UK discussions post-Biogen recognized concerns about per se claims that extend protection beyond what is disclosed; the Supreme Court and Lords indicated there is risk if the broad claim is not sufficiently enabled across the claimed range.
The “one way” rule in Biogen was rejected in Generics v Lundbeck: disclosing one way to make a product can be enough for enabling a product claim, provided the disclosure covers the product and common general knowledge enables the skilled person to reproduce it.
The plausibility approach: in many cases involving large classes (especially chemical compounds), a principle of general application enabling substantially all members may suffice if there is a plausible basis for generalization; however, the court must be cautious to ensure that enablement actually covers the whole claimed class.

Classes of compounds (2.3.5)

Patents can be granted for very large classes (DNA sequences, large sets of chemical compounds).
The test is similar to simple devices: enabling the invention without undue burden; in many cases, a common general principle allows class-wide protection.
However, the class must be unified by a principle that supports general application; absent a unifying principle, the claim may be too broad and not sufficiently disclosed.
The Genentech line (plasmids, polypeptides, etc.) suggests that if a general principle applies, broader claims may be allowed, provided the specification discloses a general principle shared by all members of the class.
Plausibility (or reasonable prediction) has become increasingly relevant, especially in drug patents: the specification must disclose a plausible expectation of the claimed effect, not just a speculative guess; this is linked to the balance between enabling disclosure and preventing armchair patenting.
Supreme Court cases like Regeneron have clarified that the asserted general principle must enable a substantial part of the claimed range; mere plausibility does not automatically satisfy enablement for the entire range.

Insufficiency due to Uncertainty (2.4)

Prior to the 1977 Act, ambiguity could lead to revocation; now the ground arises when claims are not clear and concise, creating a potential ground for insufficiency.
2.4.1 The recognition of the ground (Kirin-Amgen): clarity can be used to revoke for sufficiency if the boundary of the invention cannot be ascertained; claims may be disputed for insufficiency when it prevents the skilled person from performing the invention.
2.4.2 What level of uncertainty?
- Distinguishes fuzzy/unclear claims from truly uncertain ones.
- If a claim is too vague to know whether it covers the invention or to carry the invention out, it may be insufficient.
- Kirin-Amgen clarified that lack of clarity can be treated as insufficiency when it prevents enablement; but later rulings recognize that uncertainty in drafting can be handled by other provisions (e.g., lack of support or clarity, not directly sufficiency).
Consequences: non-compliance with clarity/support provisions can indirectly affect sufficiency; post-grant amendments may rely on s14(5)(c) and Art. 84 to assess issues but not as direct grounds for revocation—however, combination of these standards can affect sufficiency determination.

Claims (3)

Central role: claims define the scope of protection; they must be clear, concise, and supported by the description; must relate to a single invention or a unified group of inventions.
3.1 Clarity: claims must be clear and concise under Art. 84 (and s. 14(5)(c)); the notional skilled addressee reads the claims; even imprecise terms may be permissible if generally understood in the field.
3.2 Supported by the Description: claims must be supported by the description; this ensures a correlation between what is invented and what is claimed and helps third parties determine infringement.
3.3 Unity of Invention: claims must relate to one invention or to a single inventive concept; if multiple inventions appear, there must be a single inventive concept linking them; otherwise, unity of invention is violated.
Clarity and support are important for translating plurality of claims, and for ensuring that a patent provides a coherent monopoly.

Improper Amendments (4)

There are two main limits on amendments:
- 4.1 Restrictions on Amendments that Add Matter: amendments cannot introduce subject matter beyond content of the application as filed; amendments must not add new matter that extends beyond the original disclosure.
- 4.2 Amendments that Extend the Scope of Protection: after grant, amendments must not extend the protection conferred by the patent; extending the scope after grant is generally restricted; narrowing the claims is usually permitted if it does not introduce new matter.
Rationale: protects third parties relying on the original disclosure; prevents patentees from inserting information after filing to broaden protection.
The standard for added matter: compare the amended specification with the original application; the skilled person should not learn anything from the amended version that was not disclosed originally.
Examples and guiding cases:
- Ward’s Application (illustrative): adding references to plant pot bases when the original disclosed nested pots breached the added matter rule.
- EPO G 2/10 (Disclaimer) and G 1/16 (Disclaimer III): clarifications on disclaimers and added matter.
- Akse: removing essential features versus adding non-essential features (removal can sometimes introduce added matter if essential features are removed).
Broadening vs narrowing: broadening is allowed pre-grant if no new matter; post-grant, broadening amendments are generally not allowed; changes from one type of claim (e.g., compound) to another (e.g., use) may be permissible if the scope relates to the same inventive concept and does not introduce new matter.

Deposits and Biological Material (Biotech-specific) (integrated in 2.2.1)

Deposits: for biological inventions involving material that cannot be described to enable the invention, deposit at a recognized institution may satisfy sufficiency.
Conditions: deposit must be referenced in the patent; depositary institutions include Budapest Treaty members; the deposition does not become prior art until publication.
The Wisconsin Alumni Foundation/Stem Cell decision: confirms how deposits can be used to support sufficiency under Article 83; the decision stands for enabling disclosure in biotech cases where description alone may be insufficient.
The Biotech Directive and EPC correspond to these deposit provisions; the deposit is an option, not an obligation; in some cases, description may be sufficient without deposit depending on the invention’s nature and the art field.

Plausibility and Post-Grant Considerations (2.3 – 2.5 themes overlapping with 2.3 and 2.4)

Plausibility/Reasonable Prediction: in drug patents and large-class claims, courts consider whether the specification provides a plausible basis for the asserted effect, not mere armchair speculation.
Regeneron and subsequent cases emphasize that while a general principle enabling a broad class may be allowed, enabling the full scope requires a credible, plausible basis to support the claimed embodiments.
The concept of plausibility helps ensure that the scope of the monopoly is commensurate with what the invention can actually enable, preventing overbreadth in real terms.

Key Cases and Authorities (illustrative map)

Regeneron Pharmaceuticals v. Kymab [2020] UKSC 27; UK Supreme Court decision emphasizing alignment of claim scope with the technical contribution and enabling disclosure; analysis of product vs process and the breadth of claims.
Generics (UK) v. Lundbeck [2007] EWHC 1040; [2008] EWCA Civ 311; [2009] UKHL 12; case series clarifying product claims, enabling disclosure, and scope of protection for products vs processes.
Biogen v. Medeva [1997] RPC 1; foundational for Biogen insufficiency; emphasizes how enablement interacts with wide class claims and added matter constraints; introduced the idea of a general application principle for enabling general classes.
Kirin-Amgen v. Transkaryotic Therapies [2002] EWCA Civ 1096; [2003] RPC (3) 31; [2004] UKHL 46; clarified the role of clarity and sufficiency post-grant; distinguished between “inventive concept” and “technical contribution.”
Kirin-Amgen v. Hoechst Marion Roussel [2004] UKHL 46; elaborates on the boundary between clarity and sufficiency.
Warner-Lambert v. Generics [2018] UKSC 56; discusses plausibility and the scope of sufficiency in the modern context; supports the idea that plausibility can be a relevant factor in sufficiency analysis.
Genentech/Polypeptide Expression (T 292/85; 1989) and related Genentech lineage; helps distinguish between product vs process contributions and general principles enabling broad classes.
Exxon/Fuel Oils (T 409/91; 1994) and related decisions; provide frameworks for assessing enablement in chemical inventions.
Ward’s Application (illustrative) and other EPO guidelines (H-IV; F- IV) for add-matter and broadening guidelines.
Wisconsin Alumni Research Foundation/Stem Cell (T 1374/04; 2007 OJ EPO 313) for deposit-related enablement issues in biotech.
Mycogen/Modifying Plant Cells (T 694/92; 1998) and related plant biotech decisions; emphasize that trials and non-inventive steps are allowed for enabling disclosure, but not if they require inventive steps.
Biogen sufficiency field in post-2004 jurisprudence (e.g., Regeneron, FibroGen line) framing plausibility and general application principles in enabling disclosures.

Practical Implications and Real-World Relevance

Drafting strategy: when pursuing broad claims (especially product claims or large classes), ensure the description discloses a credible basis for enabling the entire scope; if not, anticipate Biogen insufficiency challenges.
For biotech and chemical inventions, consider deposits when the invention cannot be fully described in words; ensure deposit reference is included if relied upon for sufficiency.
For broad product claims, avoid overbreadth by ensuring that the claimed scope is justified by the technical contribution and supported by the description; consider whether a single enabling embodiment suffices or whether multiple embodiments are needed.
Clarity and unity are essential: ensure that claims are not ambiguous and that unity of invention is maintained to avoid invalidity based on multiple inventive concepts.
Post-grant amendments: understand that amendments cannot add new matter or extend protection, and changes in claim categories (e.g., from composition to use) can be allowed if they do not extend the scope beyond what was originally disclosed and do not introduce new matter.
The evolving concept of plausibility means that patentees should provide credible evidence or reasoning to support the claimed effects, particularly for pharmaceuticals and large classes of compounds.

Quick Reference: Key Sections and Terms (LaTeX-formatted references)

Sufficiency of disclosure tests: enabling disclosure; scope of monopoly vs. disclosure; classic insufficiency; Biogen insufficiency; uncertainty. See § 2.2, § 2.3, § 2.4.
Core statutory references and art.
- Patents Act 1977: sections $14(3)$ , $14(5)(c)$ , $72(1)$ , $s. 32(1)(i)$ .
- EPC: Article $83$ , Article $84$ , Article $100$ , Article $123(3)$ , Article $82$ .
Concepts:
- Enabling disclosure: ext{Enablement}
  ightleftharpoons ext{practice by a skilled person with common general knowledge}
- Technical contribution: the information contributed to the art; distinct from the inventive concept.
- Plausibility: a reasonable prediction of the claimed effect at filing; too speculative claims may fail to be plausible.
- Unity of invention: claims must relate to one inventive concept.

Summary Verdicts to Remember

A product claim is sufficiently enabled if the product is disclosed and one valid way of making the product is disclosed, with the skilled person able to reproduce it using common general knowledge; breadth must be justified by the technical contribution.
Biogen insufficiency arises when the breadth of the claims exceeds what the disclosure enables; the invention’s contribution must justify the scope of protection.
Clarity and support remain critical post-grant; although lack of clarity may not be a direct ground for revocation, it can indirectly undermine sufficiency and enforcement.
Deposits provide a practical mechanism to enable biological inventions; ensure reference to deposits if relied upon for sufficiency.

Final Thoughts

Internal requirements are as important as external criteria in patent law. A well-crafted patent not only discloses the invention adequately but also aligns the scope of protection with the technical contribution and supports it with a clear, concise, and unified claim set. The evolving jurisprudence emphasizes a careful balance between enabling breadth, plausible predictions for therapeutic effects, and the need to prevent opportunistic broad claims that extend beyond what the inventor has disclosed.